DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia

Leuk Lymphoma. 2016 Aug;57(8):1969-73. doi: 10.3109/10428194.2015.1122785. Epub 2015 Dec 24.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute Disease
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cell Transformation, Neoplastic / genetics
  • DNA (Cytosine-5-)-Methyltransferases / genetics*
  • DNA Methyltransferase 3A
  • DNA-Binding Proteins / genetics*
  • Dioxygenases
  • Humans
  • Janus Kinase 2 / genetics*
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / genetics*
  • Male
  • Middle Aged
  • Mutation*
  • Polycythemia Vera / genetics*
  • Proto-Oncogene Proteins / genetics*
  • Remission Induction
  • Time Factors

Substances

  • DNA-Binding Proteins
  • DNMT3A protein, human
  • Proto-Oncogene Proteins
  • Dioxygenases
  • TET2 protein, human
  • DNA (Cytosine-5-)-Methyltransferases
  • DNA Methyltransferase 3A
  • JAK2 protein, human
  • Janus Kinase 2